Sign In
Buy TGTX
$40.11
+3.47 (+9.47%)
At Close: Jun 03, 2026
Why Is TG Therapeutics (TGTX) Up 4.7% Since Last Earnings Report?
12:36pm, Wednesday, 03'rd Sep 2025
TG Therapeutics (TGTX) reported earnings 30 days ago. What's next for the stock?
TG Therapeutics Announces Completion of Existing Share Repurchase Program and Authorization of New $100 Million Program
07:30am, Wednesday, 03'rd Sep 2025
NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that it has completed its previously authorized $100 million share repurchase program, which was initi
TG Therapeutics to Participate in the Cantor Global Healthcare Conference
08:00am, Thursday, 28'th Aug 2025
Fireside chat scheduled for Wednesday, September 3, 2025, at 10:20am ET Fireside chat scheduled for Wednesday, September 3, 2025, at 10:20am ET
TGTX Down as Q2 Earnings Miss Mark, Briumvi Sales Drive Top Line
01:15pm, Tuesday, 05'th Aug 2025
TG Therapeutics slides 18% as second-quarter earnings fall short despite a 92% revenue jump fueled by surging Briumvi sales.
TG Therapeutics Q2 Revenue Up 91%
12:23pm, Monday, 04'th Aug 2025
TG Therapeutics Q2 Revenue Up 91%
TG Therapeutics, Inc. (TGTX) Q2 2025 Earnings Call Transcript
10:19am, Monday, 04'th Aug 2025
TG Therapeutics, Inc. (NASDAQ:TGTX ) Q2 2025 Earnings Conference Call August 4, 2025 8:30 AM ET Company Participants Adam Waldman - Chief Commercialization Officer Jenna Bosco - Senior Vice President
TG Therapeutics (TGTX) Misses Q2 Earnings Estimates
09:11am, Monday, 04'th Aug 2025
TG Therapeutics (TGTX) came out with quarterly earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.32 per share. This compares to earnings of $0.04 per share a year ago.
TG Therapeutics Reports Second Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance
07:00am, Monday, 04'th Aug 2025
Second quarter 2025 total revenue of $141.1 million, including BRIUMVI U.S. net revenue of $138.8 million Raises full year 2025 BRIUMVI U.S. net revenue target to approximately $570 - $575 million Con
TG Therapeutics to Host Conference Call on Second Quarter 2025 Financial Results and Business Update
07:30am, Wednesday, 30'th Jul 2025
NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, August 4, 2025, at 8:30 AM ET to discuss results for the
TG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q2 Release
11:10am, Tuesday, 29'th Jul 2025
TG Therapeutics (TGTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TG Therapeutics: Another Possible Avenue Of MS Growth With Azer-Cel
04:05pm, Wednesday, 25'th Jun 2025
TG Therapeutics, Inc.'s BRIUMVI saw Q1 2025 revenue surge 137% YoY to $119.7M, driven by strong U.S. growth. A subcutaneous version of TGTX's BRIUMVI is in phase 1 trials, with late-stage development
TG Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
07:30am, Friday, 06'th Jun 2025
NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will participate in the Gold
TG Therapeutics: Estimates Could Soon Be Raised Again
06:00am, Wednesday, 28'th May 2025
TG Therapeutics remains on track, with Q1 revenue matching my model and potential for 110% growth in 2025 if price increases hold. Analyst estimates for 2025 revenue have risen sharply, and Q2 expecta
NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with
TG Therapeutics Falls Short On Earnings, But Briumvi Sales Steal the Show
04:37pm, Monday, 05'th May 2025
TG Therapeutics Inc TGTX on Monday reported first-quarter earnings per share of 3 cents, a shift from a loss of 7 cents a year ago, but below the consensus of 17 cents.
